Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Belimumab Treatment for IgG4-related Disease

during the treatment. Belimumab is an IgG1-lambda monoclonal antibody that prevents the survival of B lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Phase 1 Evaluation of the Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

infections. Low levels of CD4 cells may make a person more likely to get sick. There are no approved treatments for ICL. Researchers think a drug called belimumab may be able to help in specific situations

  • 109 views
  • 17 Oct, 2022
  • 1 location
Synergetic B-cell Immunomodulation in SLE - 2nd Study. (SynBioSe-2)

-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.

anti-dna antibodies
nephritis
baff
elisa
mycophenolate
  • 28 views
  • 27 Apr, 2022
  • 4 locations
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with relapsed and/or refractory SLE.

  • 0 views
  • 04 Oct, 2022
  • 1 location
The BeLimumab Antiphospholipid Syndrome Trial (BLAST) (BLAST)

AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL

glycoprotein
warfarin
haemostasis
lupus
thrombosis
  • 40 views
  • 05 Jun, 2022
  • 1 location
Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR)

This study is a phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia (CLL). Treatment of CLL has drastically

  • 0 views
  • 25 Mar, 2022
Efficacy and Safety of Belimumab in SLE Patients

problems. Belimumab is the only FDA-approved biological agent for SLE. Data showed that treatment with belimumab on the background of standard therapy was effective in active SLE patients. However, the

autoimmune disease
tacrolimus
biologics
lupus
treatment regimen
  • 0 views
  • 14 Jun, 2022
  • 1 location
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (COMBIVAS)

Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and

anti-neutrophil cytoplasmic antibody
anca
microscopic polyangiitis
prednisolone
rituximab
  • 19 views
  • 09 Feb, 2022
  • 1 location
Sequential Belimumab and T-cell Based Therapy in SLE

are produced by a specific type of white blood cells called B cells. Belimumab (Benlysta®) is a monoclonal antibody against the B cells by blocking the action of BLyS, a protein that prolongs the

benlysta
belimumab
monoclonal antibodies
baff
lupus
  • 0 views
  • 23 Dec, 2021
  • 1 location
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Belimumab (Benlysta ®) is a human

Accepts healthy volunteers
  • 0 views
  • 28 May, 2022
  • 1 location